Clinical trials: Colorectal Liver Metastases (CRCLM)
Colorectal Liver Metastases (CRCLM)
To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases
Both drug-eluting bead transarterial chemoembolization (DEB-TACE) and hepatic arterial infusion chemotherapy (HAIC) are recommended for unresectable colorectal liver metastases (CRLM) treatment.
- Trial name
- NCT05889325
- Testing
- DEB-TACE plus HAIC
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer Liver Metastasis
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to…
- Trial name
- NCT06590259
- Testing
- Multi-mode tumor treatment system, Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 6th People's Hospital
CRC (Colorectal Cancer)
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.
- Trial name
- NCT07728019
- Testing
- SCRT, Retlirafusp alfa Injection, Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Colorectal Cancer, Liver Metastases
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
The aim of the trial is to compare the objective response rates of FUDR/Oxaliplatin HAI plus CPT-11 and FOLFOXIRI chemotherapy in patients with initially non-resectable metastatic colorectal cancer liver metastases.
- Trial name
- NCT03678428
- Testing
- Irinotecan, Oxaliplatin HAI, Floxuridine
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-sen University
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
Colorectal Cancer Liver Metastases
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
The incidence of colorectal cancer liver metastasis is high and the prognosis is poor. Improving the treatment effect of colorectal cancer liver metastasis is the key to improving the prognosis of colorectal cancer patients.
- Trial name
- NCT05485909
- Testing
- Radiofrequency ablation, Regorafenib and Toripalimab Combination
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Colo-rectal Cancer, Liver Metastases
A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis.
- Trial name
- NCT03493061
- Testing
- Irinotecan, Oxaliplatin, Floxuridine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Liver Metastasis Colon Cancer, ctDNA Genotype
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM).
- Conditions
- Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment
- Trial name
- NCT06199232
- Testing
- HAIC+targeted therapy+PD-1 inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking University
Colorectal Cancer, Liver Metastases
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis of RAS wildtype.
- Trial name
- NCT03493048
- Testing
- Irinotecan, Cetuximab, 5-fluorouracil
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Sun Yat-sen University